Loading stock data…
$223.21-3.79 (-1.67%)
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Ascendis Pharma A/S in the Healthcare sector is trading at $223.21 with a market capitalization of $15.0B. Wall Street consensus targets $305.09 (20 analysts), implying a +36.7% move over the next 12 months. The stock is currently 21% below its 52-week high of $282.15, remaining 5.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $339.29M↑ | $246.60M↓ | $247.50M↑ | $213.63M↑ | $158.04M |
| Gross Profit | $311.63M↑ | $229.09M↑ | $223.90M↑ | $191.28M↑ | $126.60M |
| Operating Income | $220.47M↑ | $24.81M↑ | $6.44M↓ | $11.00M↑ | -$52.95M |
| Net Income | $206.97M↓ | $629.34M↑ | -$33.56M↑ | -$60.99M↓ | -$38.85M |
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients wi...